Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care

Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC

June 2nd 2023

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Advanced NSCLC: Interpreting Data From the POSEIDON Trial

May 26th 2023

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations

May 26th 2023

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer

May 19th 2023

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing

May 19th 2023

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Factors in Selecting IO Therapy for Patients With Advanced NSCLC

May 12th 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Considerations for Incorporating Perioperative Treatment in Resectable NSCLC

May 12th 2023

Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.

Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer

May 5th 2023

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies

April 28th 2023

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer

April 28th 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

Experts on Second-Line Treatment Options for EGFR TKI-Resistant NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.

Updates on I/O Therapy for Non-Driver mNSCLC

September 1st 2020

EGFR Exon 20 Mutations in NSCLC

September 1st 2020

KRAS-Mutant NSCLC

September 1st 2020

HER2 Targeted Therapy for Treatment of NSCLC

September 1st 2020

MET Exon 14 Mutations in mNSCLC

September 1st 2020

RET Fusion+ mNSCLC

September 1st 2020

Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC

July 9th 2020

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Dr. Halmos on Recent Advancements in Non–Small Cell Lung Cancer

June 23rd 2020

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Dr. Halmos on Actionable Biomarkers in NSCLC

November 12th 2019

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.